Literature DB >> 12883230

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Gisa Gerstenberg1, Toshiaki Aoshima, Takashi Fukasawa, Keizo Yoshida, Hitoshi Takahashi, Hisashi Higuchi, Yoshiko Murata, Ritsuko Shimoyama, Tadashi Ohkubo, Tetsuo Shimizu, Koichi Otani.   

Abstract

The effects of the cytochrome P450 (CYP) 2D6 genotype and cigarette smoking on the steady-state plasma concentrations (C(ss)) of fluvoxamine (FLV) and its demethylated metabolite fluvoxamino acid (FLA) were studied in 49 Japanese depressed patients receiving FLV 200 mg/d. The C(ss) of FLV and FLA were measured by HPLC, and the wild-type allele (*1) and two mutated alleles causing absent (*5) or decreased (*10) CYP 2D6 activity were identified by PCR methods. The patients were divided into three genotype groups by the number of mutated alleles: 12 cases with no (*1/*1), 27 cases with one (*1/*5 and *1/*10), and 10 cases with two (*5/*10 and *10/*10) mutated alleles. The means +/- SD of the C(ss) of FLV and FLA and the FLA/FLV ratio of all patients were 169.1 +/- 147.5 ng/mL, 83.9 +/- 52.7 ng/mL, and 0.71 +/- 0.50, respectively. The C(ss) of FLV and FLA were not significantly different among the three genotype groups. However, the FLA/FLV ratio was significantly lower in the patients with one (P < 0.05) and two (P < 0.01) mutated alleles than in those with no mutated allele. There was no significant difference between nonsmokers (n = 34) and smokers (n = 15) in these values. In the stepwise multiple regression, the C(ss) of FLA (P < 0.05) and FLA/FLV ratio (P < 0.001) showed significant negative correlations with the number of mutated alleles, and the FLA/FLV ratio was significantly (P < 0.05) lower in women than in men. The present study suggests that the CYP 2D6 genotype and cigarette smoking have no major impact on the C(ss) of FLV and FLA, though CYP 2D6 is involved in the demethylation of FLV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883230     DOI: 10.1097/00007691-200308000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.

Authors:  Rocco Orlando; Sara De Martin; Laura Andrighetto; Maura Floreani; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 3.  Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

Authors:  N Lynn Henry; Vered Stearns; David A Flockhart; Daniel F Hayes; Michelle Riba
Journal:  Am J Psychiatry       Date:  2008-10       Impact factor: 18.112

Review 4.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

Review 5.  Smoking and antidepressants pharmacokinetics: a systematic review.

Authors:  Pedro Oliveira; Joana Ribeiro; Helena Donato; Nuno Madeira
Journal:  Ann Gen Psychiatry       Date:  2017-03-06       Impact factor: 3.455

6.  Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.

Authors:  Mikhail Sergeevich Zastrozhin; Elena Anatolievna Grishina; Nataliya Petrovna Denisenko; Valentin Yurievich Skryabin; Dmitry Dmitrievich Markov; Ludmila Mikhailovna Savchenko; Evgeny Alekseevich Bryun; Dmitry Alekseevich Sychev
Journal:  Pharmgenomics Pers Med       Date:  2018-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.